Navigation Links
Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
Date:2/12/2008

- Management to discuss fourth quarter financial results -

LAVAL, QC, Feb. 12 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Thursday, February 21 at 8:30 a.m. (ET) to discuss its fourth quarter 2007 financial results. Labopharm will report its fourth quarter 2007 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3418 or 1-800-732-0232. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, February 28, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21260670 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the price of the Company's shares, the uncertainties related to the regulatory process for drug approval and the commercialization of the Company's products, if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Pet obesity ... and 54% of dogs, according to the Association for Pet Obesity Prevention (APOP). During ... key pet food issues such as the benefits of corn and grains, value of ...
(Date:2/22/2017)... ... 2017 , ... FPS is a nonprofit mental health agency ... 1977, our organization was at the forefront in working with veterans with PTSD-related ... evident and served as the catalyst for the establishing the agency. , Run ...
(Date:2/22/2017)... ... February 22, 2017 , ... In ... many different solutions on the market, it is easy to start feeling frustrated ... Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, There ...
(Date:2/22/2017)... Wis (PRWEB) , ... February 22, 2017 , ... ... a category by itself - the Vectorâ„¢ Series Multi-Cook Oven offers up to ... oven chamber, featuring exclusive Structured Air Technologyâ„¢ for unmatched evenness in cooking. Alto-Shaam ...
(Date:2/22/2017)... NORTHERN CALIFORNIA (PRWEB) , ... February 22, 2017 ... ... expand the pipeline and the number of African American/Black students who want to ... and residents to pursue their careers as physicians in the Oakland/San Francisco Northern ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 The Senior Care Pharmacy Coalition ... and House of Representatives that will curtail the ability ... -- from extracting retroactive direct and indirect remuneration (DIR) ... pharmacies and the Medicare program. S. 413, ... and Jon Tester (D-MT), and House companion ...
(Date:2/22/2017)... MELVILLE, N.Y. , Feb. 22, 2017 /PRNewswire/ ... has signed an exclusive distribution agreement with Rijuven, ... its CardioSleeve diagnostic device to medical practitioners. ... records synchronized electrocardiogram (ECG) and heart sound signals, ... via Bluetooth, and offers cloud-based analysis to help ...
(Date:2/22/2017)... Feb. 22, 2017  Allergan plc (NYSE: AGN), ... be a Gold sponsor of the Alzheimer,s Foundation ... Tour." This tour commemorates AFA,s15 years of educating ... and programs. The tour will include AFA,s free ... and displays of the AFA Quilt to Remember. ...
Breaking Medicine Technology: